Pharmaceutical News

RSS

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease.

30 Apr 2016

New oral cancer drugs getting more expensive over time, study shows

New cancer drugs taken in pill form have become dramatically more expensive in their first year on the market compared with drugs launched 15 years ago, a University of North Carolina at Chapel Hill study has found. The findings call into question the sustainability of a system that sets high prices at market entry in addition to rapidly increasing those prices over time.

30 Apr 2016

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets.

30 Apr 2016

New therapeutic target to treat bacterial infections may substitute antibiotics

Infections continue to threaten human health. With remarkable genetic flexibility, pathogenic organisms outsmart available therapies. Fortunately, microbial versatility is matched by the host immune system, which evolves in dialogue with the microbes. Therapies that enhance the beneficial effects of the immune response represent a promising, but under-explored, therapeutic alternative to antibiotics.

29 Apr 2016

Understanding how individuals respond to aspirin

Researchers have learned new information about how different people respond to aspirin, a globally prescribed drug in cardioprotection. The research team, led by scientists at Cardiff University in the United Kingdom and including representatives from the University of Alabama at Birmingham and the University of Colorado, identified more than 5,600 lipids — or fats — in blood platelets and gained new insights into how these cells respond to aspirin.

29 Apr 2016

New version of obesity drug could help people reduce weight without experiencing anxiety, depression

A new version of an obesity drug that caused serious psychiatric side effects could help people lose pounds without experiencing the anxiety, depression and suicidal thoughts previously associated with it. The research, published in Bioorganic and Medicinal Chemistry, shows that the new version of the drug can still work without reaching the brain in rats, avoiding the side effects.

29 Apr 2016

Black raspberry intake can lower key measure of arterial stiffness in patients with metabolic syndrome

A new study shows that black raspberry extract can significantly lower a key measure of arterial stiffness-an indicator of cardiovascular disease. Black raspberry intake was also associated with increased levels of circulating endothelial progenitor cells (EPCs), which help repair and regenerate damaged arteries, according to the study published in Journal of Medicinal Food, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Medicinal Food website until May 28, 2016.

29 Apr 2016

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

29 Apr 2016

Probiotic supplements may help treat post-menopausal osteoporosis

Probiotic supplements protected female mice from the loss of bone density that occurs after having their ovaries removed, researchers at Emory University School of Medicine and Georgia State University have shown.

28 Apr 2016

$Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing$

Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing

In people with osteoporosis, one fracture often leads to more fractures, and potentially a future of pain, disability, and poor quality of life. While studies have shown that such high-risk patients benefit from appropriate medication to reduce future fracture risk, more research is needed on the effect of osteoporosis medications on fracture healing.

28 Apr 2016

Experimental cancer drug Nutlin-3 shows promise in cancelling effects of fragile X syndrome

A University of Wisconsin-Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.

28 Apr 2016

Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

The rise of antibiotic resistant bacterial pathogens is an increasingly global threat to public health. In the United States alone antibiotic resistant bacterial pathogens kill thousands every year.

27 Apr 2016

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Since 2006, several published studies have associated the use of some acid suppression medications in hospitalized high-risk babies with infections, necrotizing enterocolitis and increased risk of death. Those medications - histamine-2 receptor antagonists, such as ranitidine (Zantac and others), and proton pump inhibitors, such as esomeprazole (Nexium and others) - were originally approved by the U.S. Food and Drug Administration for use in adults and older children.

27 Apr 2016

Rapamycin drug could target neural damage linked to Leigh syndrome

Salk Institute scientists showed how an FDA-approved drug boosts the health of brain cells by limiting their energy use. Like removing unnecessary lighting from a financially strapped household to save on electricity bills, the drug--called rapamycin--prolongs the survival of diseased neurons by forcing them to reduce protein production to conserve cellular energy.

27 Apr 2016

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy.

27 Apr 2016

WHO reminds Angola travellers to receive yellow fever vaccination

As efforts to bring an outbreak of yellow fever in Angola under control continue, the World Health Organization is reminding all travellers to the country that they are required to receive the yellow fever vaccination and to have a valid certificate of vaccination to prove that they are protected from the disease and to prevent its further spread.

27 Apr 2016

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

First-ever vaccine to combat Leishmaniasis under development

As scientists scramble to get a Zika virus vaccine into human trials by the end of the summer, a team of researchers is working on the first-ever vaccine to prevent another insect-borne disease - Leishmaniasis - from gaining a similar foothold in the Americas.

27 Apr 2016

Cholesterol-lowering drugs may not reduce colorectal cancer risk

Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.

27 Apr 2016

Administering flu vaccinations in the morning could induce greater antibody responses

New research from the University of Birmingham has shown that flu vaccinations are more effective when administered in the morning.

26 Apr 2016

Pharmaceutical News

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

New oral cancer drugs getting more expensive over time, study shows

First generic version of Crestor gets FDA approval

New therapeutic target to treat bacterial infections may substitute antibiotics

Understanding how individuals respond to aspirin

New version of obesity drug could help people reduce weight without experiencing anxiety, depression

Black raspberry intake can lower key measure of arterial stiffness in patients with metabolic syndrome

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Probiotic supplements may help treat post-menopausal osteoporosis

Multidisciplinary experts assess effects of osteoporosis drugs on fracture healing

Experimental cancer drug Nutlin-3 shows promise in cancelling effects of fragile X syndrome

Existing non-antibiotic therapeutic drugs could help combat antibiotic-resistant pathogens

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Rapamycin drug could target neural damage linked to Leigh syndrome

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

WHO reminds Angola travellers to receive yellow fever vaccination

Regular aspirin use may help reduce risk of bile duct cancer

First-ever vaccine to combat Leishmaniasis under development

Cholesterol-lowering drugs may not reduce colorectal cancer risk

Administering flu vaccinations in the morning could induce greater antibody responses

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News